Search
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalCinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting … Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain.
Synonyms: 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine, 1-Benzhydryl-4-cinnamylpiperazinCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Synonyms: (R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID, ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACIDCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [A265065] Mirdametinib selectively and potently inhibits the MEK1/2 enzymes.[A265065]
Synonyms: (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE, N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDECategories: P-glycoprotein substratesGadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigationalEthoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]
Categories: Compounds used in a research, industrial, or household settingProducts: PRIMOVIST® SOLUCIÓN INYECTABLE, PRIMOVIST 0,25 MMOL/ML ENJEKSIYON ICIN COZELTI ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … [A275476] Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecule structure enables once-daily oral dosing without food
Synonyms: 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3, 3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(Categories: GLP-1 Agonists, Cytochrome P-450 SubstratesAtomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A18262] Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. … Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesProducts: STRATTERA® 80 MG, ATTENTHO®25 MG CAPSULASLevoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsBebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnIt binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. … in the US.
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Products: EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 3 ADET